One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

International Journal of Obesity

Volumn 24, Issue 3, 2000, Pages 306-313

  Finer, N ^a   James, W P T ^b   Kopelman, P G ^c   Lean, M E J ^d   Williams, G ^e  

^a LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Cardiovascular risk factors; Gastrointestinal lipase inhibitor; Orlistat; Pharmacotherapy; Weight loss

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; VITAMIN;

ABDOMINAL PAIN; ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BACKACHE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INFLUENZA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LOW CALORY DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBESITY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION; VITAMIN BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

EID: 0034095342     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801128     Document Type: Article

References (32)

1. 1 Higgins M, Kannel W, Garrison R, Pinsky J, Strokes J III. Hazards of obesity. The Framingham experience Acta Med Scand 1988; 723(Suppl): 23-36.
2. 2 Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993; 119: 655-660.
3. 3 Department of Health. The health survey for England. HMSO: London, 1998.
4. 4 Department of Health. The health of the nation: a strategy for health in England. HMSO: London, 1992.
5. 5 Bouchard C (ed). The genetics of obesity. CRC Press: Boca Raton, FL, 1994.
6. 6 Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? Br Med J 1995; 7002: 437-439.
7. 7 Hyman FN, Sempos E, Saltsman J, Glinsmann WH. Evidence for success of caloric restriction in weight loss and control. Summary of data from industry. Ann Intern Med 1993; 119: 681-687.
8. 8 Goldstein DJ, Parvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60: 647-657.
9. 9 A report by the Royal College of Physicians. Clinical management of oveweight and obese patients with particular reference to the use of drugs. Royal College of Physicians, 1998.
10. 10 Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. New Engl J Med 1997; 337: 581-588.
11. 11 Cannistra LB, Davis SM, Bauman AG. Valvular heart disease associated with dexfenfluramine. New Engl J Med 1997; 337: 636.
12. 12 Fenfluramine and dexfenfluramine withdrawn. Report from the Medicines Control Agency. Curr Probl Pharmacovig 1997; 23: 13-14.
13. 13 Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55: 309S-313S.
14. 14 Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, Patel IH. Retrospective population-based analysis of the dose - response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56: 82-85.
15. 15 Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von Bergmann K, Strobel W, Sjöström L, van der Veen EA. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes 1995; 19: 221-226.
16. 16 Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Scheuten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmac 1994; 46: 405-410.
17. 17 Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M, for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-172.
18. 18 Davidson MH, Hauptman J, GiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999; 281: 235-242.
19. 19 Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288-1294.
20. 20 Scottish Intercollegiate Guidelines Network. The management of obese patients in Scotland - integrating a new approach in primary health care with a national prevention and management strategy. SIGN, Royal College of Physicians: Edinburgh, 1996.
21. 21 Schofield WN. Predicting basal metabolic rate, new standards and review of previous work; human nutrition. Clin Nutr 1985; 39C(Suppl 1): 5-41.
22. 22 Han TS, van Leer EM, Seidell JC, Lean MEJ. Waist circumference as a screening tool for cardiovascular risk factors: evaluation of Receiver Operating Characteristics (ROC). Obes Res 1996; 4: 533-547.
23. 23 Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Br Med J 1995; 311: 158-161.
24. 24 Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; 2: 1142-1145.
25. 25 Lissner L, Heitmann BL. Dietary fat and obesity: evidence from epidemiology. Eur J Clin Nutr 1995; 49: 79-90.
26. 26 Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 6: 397-415.
27. 27 Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking US white women aged 40-64 years. Am J Epidemiol 1995; 141: 1128-1141.
28. 28 Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999; 149: 491-503.
29. 29 Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990; 7: 228-232.
30. 30 Paumgartner G, Sauerbruch. Gallstones: pathogenesis. Lancet 1991; 338: 1117-1121.
31. 31 Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmac 1996; 36: 647-653.
32. 32 Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmac 1996; 36: 152-159.